Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Cullinan Oncology
company
About
Cullinan Oncology is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $150M
- Industries
- Biopharma,Biotechnology,Medical Device
- Founded date
- Jan 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$150M
Cullinan Oncology has raised a total of
$150M
in funding over 2 rounds. Their latest funding was raised on
Oct 3, 2017 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 3, 2017 | Series A | $150M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Cullinan Oncology is funded by 2 investors.
UBS Oncology Impact Fund
and Park Vale Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Park Vale Capital
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
